Robert A. Belderbos

591 total citations
14 papers, 283 citations indexed

About

Robert A. Belderbos is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Biotechnology. According to data from OpenAlex, Robert A. Belderbos has authored 14 papers receiving a total of 283 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 4 papers in Biotechnology. Recurrent topics in Robert A. Belderbos's work include Occupational and environmental lung diseases (10 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Pleural and Pulmonary Diseases (6 papers). Robert A. Belderbos is often cited by papers focused on Occupational and environmental lung diseases (10 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Pleural and Pulmonary Diseases (6 papers). Robert A. Belderbos collaborates with scholars based in Netherlands, Italy and United Kingdom. Robert A. Belderbos's co-authors include Joachim G.J.V. Aerts, Heleen Vroman, Robin Cornelissen, Rossana Berardi, Paul Baas, Luca Cantini, Daphne W. Dumoulin, Daan P. Hurkmans, Federica Pecci and Silvia Rinaldi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Robert A. Belderbos

13 papers receiving 283 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert A. Belderbos Netherlands 7 156 136 68 52 39 14 283
Cornedine J. de Gooijer Netherlands 10 262 1.7× 167 1.2× 39 0.6× 23 0.4× 37 0.9× 27 352
Miao Huang China 9 159 1.0× 184 1.4× 50 0.7× 44 0.8× 61 1.6× 17 298
Marie Naigeon France 9 86 0.6× 163 1.2× 78 1.1× 26 0.5× 34 0.9× 21 212
Haiqing Ni China 7 65 0.4× 207 1.5× 152 2.2× 10 0.2× 34 0.9× 10 309
Benjamin D. Medina United States 7 94 0.6× 109 0.8× 96 1.4× 21 0.4× 61 1.6× 7 263
Grégoire Marret France 8 74 0.5× 119 0.9× 31 0.5× 48 0.9× 96 2.5× 24 231
Koichiro Nozaki Japan 9 72 0.5× 133 1.0× 57 0.8× 18 0.3× 54 1.4× 16 237
Leonie K. de Klerk Netherlands 4 87 0.6× 119 0.9× 66 1.0× 41 0.8× 59 1.5× 4 219
Sheik Emambux France 8 77 0.5× 105 0.8× 34 0.5× 29 0.6× 36 0.9× 13 174
Takehiro Tozuka Japan 10 156 1.0× 198 1.5× 23 0.3× 29 0.6× 28 0.7× 33 249

Countries citing papers authored by Robert A. Belderbos

Since Specialization
Citations

This map shows the geographic impact of Robert A. Belderbos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Belderbos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Belderbos more than expected).

Fields of papers citing papers by Robert A. Belderbos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert A. Belderbos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Belderbos. The network helps show where Robert A. Belderbos may publish in the future.

Co-authorship network of co-authors of Robert A. Belderbos

This figure shows the co-authorship network connecting the top 25 collaborators of Robert A. Belderbos. A scholar is included among the top collaborators of Robert A. Belderbos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert A. Belderbos. Robert A. Belderbos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
Belderbos, Robert A., Jan H. von der Thüsen, Mieke J. Aarts, et al.. (2022). Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study. Thorax. 77(12). 1260–1267. 24 indexed citations
3.
Belderbos, Robert A., Alexander P.W.M. Maat, Sara J. Baart, et al.. (2021). Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma. JTO Clinical and Research Reports. 2(4). 100155–100155. 7 indexed citations
4.
Belderbos, Robert A., Luca Cantini, Cornedine J. de Gooijer, et al.. (2021). OA09.06 Nivolumab in Recurrent Malignant Pleural Mesothelioma: Real-World Data From Expanded Access Program In The Netherlands. Journal of Thoracic Oncology. 16(3). S123–S123. 1 indexed citations
5.
Vroman, Heleen, Robert A. Belderbos, Paul L. Klarenbeek, et al.. (2020). T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma. Journal for ImmunoTherapy of Cancer. 8(1). e000251–e000251. 23 indexed citations
6.
Belderbos, Robert A., Heleen Vroman, & Joachim G.J.V. Aerts. (2020). Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma. Frontiers in Oncology. 10. 777–777. 6 indexed citations
7.
Cantini, Luca, Federica Pecci, Daan P. Hurkmans, et al.. (2020). High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients. European Journal of Cancer. 144. 41–48. 83 indexed citations
8.
Cantini, Luca, Robert A. Belderbos, Cornedine J. de Gooijer, et al.. (2020). Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program. Translational Lung Cancer Research. 9(4). 1169–1179. 30 indexed citations
9.
Cantini, Luca, Federica Pecci, Daan P. Hurkmans, et al.. (2020). Statin treatment improves response to anti-PD1 agents in patients with malignant pleural mesothelioma and non-small cell lung cancer.. Journal of Clinical Oncology. 38(15_suppl). 3074–3074. 5 indexed citations
10.
Belderbos, Robert A., Floris Dammeijer, Mandy van Gulijk, et al.. (2019). MA12.09 Checkpoint Inhibitors Synergize with Dendritic Cell-Therapy in Pre-Clinical Models and Mesothelioma Patients. Journal of Thoracic Oncology. 14(10). S298–S299. 2 indexed citations
11.
Cantini, Luca, et al.. (2019). MA05.09 Real-World Data of Nivolumab and Pembrolizumab in Chemotherapy Pre-Treated Mesothelioma Patients. Journal of Thoracic Oncology. 14(10). S267–S267.
12.
Belderbos, Robert A., Joachim G.J.V. Aerts, & Heleen Vroman. (2019). Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment. Molecular Therapy — Oncolytics. 13. 67–81. 47 indexed citations
13.
14.
Cornelissen, Robin, Robert A. Belderbos, & Joachim G.J.V. Aerts. (2019). Abstract 2249: Checkpoint inhibitor therapy after dendritic cell vaccination elicits tumor response in mesothelioma patients. Cancer Research. 79(13_Supplement). 2249–2249. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cornedine J. de Gooijer Breakdown of academic impact, for papers by Miao Huang Breakdown of academic impact, for papers by Marie Naigeon Breakdown of academic impact, for papers by Haiqing Ni Breakdown of academic impact, for papers by Benjamin D. Medina Breakdown of academic impact, for papers by Grégoire Marret Breakdown of academic impact, for papers by Koichiro Nozaki Breakdown of academic impact, for papers by Leonie K. de Klerk Breakdown of academic impact, for papers by Sheik Emambux Breakdown of academic impact, for papers by Takehiro Tozuka
Rankless by CCL
2026